GlassScriptPhysician profile
Penny Tanner
NPI 1922156645
$1,988.98
in general payments reported to CMS, 2019-2025
12 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $159 · 2022: $302 · 2023: $272 · 2024: $228 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $709.10 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $226.05 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $223.66 | 2021-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $181.08 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $121.50 | 2025 | Auvelity |
| Corium, LLC | $118.09 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $99.55 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $83.56 | 2023-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $81.94 | 2025 | Cobenfy |
| Lundbeck LLC | $76.17 | 2023-2025 | Rexulti |
| Abbvie INC. | $56.14 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penny Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.